Tiopronin

Quick links to important sections

Tiopronin

Treatment option: Creatinine, Cystinuria

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tiopronin

Quick Facts

Property Description
Active ingredient Tiopronin (alpha-mercaptopropionylglycine, alpha-MPG)
Form Oral tablets
Pharmacological class Chelating agent; Cystine-reducing agent; Thiol compound
Common use Management of specific metabolic conditions
Origin Synthetic amino acid derivative

Tiopronin: Definition, Chemical Identity, and Classification

Tiopronin is a specialized synthetic medication whose active ingredient is the compound alpha-mercaptopropionylglycine, commonly known by its non-proprietary name, Tiopronin. It is classified as a Reducing and Complexing Thiol, distinguished chemically by the presence of a reactive sulfhydryl group in its structure. Tiopronin functions by reducing and complexing specific substances in the body. As a thiol compound, Tiopronin belongs to a high-level pharmacological class of agents designed to participate in specific chemical exchange reactions. This classification defines a class of agents capable of thiol-disulfide exchange, a fundamental chemical process.

What Type of Medicine is Tiopronin?

Tiopronin is a synthetic amino acid derivative that is typically supplied as an oral preparation in the form of tablets. The compound is chemically related to the natural amino acid L-cysteine, but its manufactured structure is engineered to serve a specific therapeutic purpose. The drug functions to chemically alter cystine, leading to compounds that are easier for the body to excrete. The general purpose of the medication is to manage metabolic conditions characterized by the formation of poorly soluble substances. It accomplishes this through a thiol-disulfide exchange mechanism, converting the problematic substance, such as cystine, into a highly soluble complex. This chemical conversion is key to maintaining proper excretion and managing the underlying metabolic imbalance.

What side effects are possible with Tiopronin?

Possible Side Effects and Safety Information

The official safety profile for Tiopronin is based on regulatory classifications of adverse reactions by frequency and physiological system, derived from sources like the U.S. Food and Drug Administration (FDA) prescribing information.


Frequency and System-Organ Classifications

Adverse reactions are formally categorized across several system-organ classes. Common reactions often involve the Gastrointestinal Disorders (diarrhea, nausea) and Skin and Subcutaneous Tissue Disorders (rash, pruritus). Other common systemic effects include fever, fatigue, and arthralgia (joint pain). A less frequent, or uncommon, reaction is ageusia (loss of taste).

Classification Examples of Reactions
Common Diarrhea, Nausea, Rash, Fever, Fatigue, Arthralgia, Pruritus
Uncommon Ageusia (Loss of taste)
Frequency Not Known Agranulocytosis, Thrombocytopenia

Serious Adverse Reactions and Safety Constraints

The most clinically significant documented safety concerns relate to Hematologic Toxicity (e.g., agranulocytosis and thrombocytopenia) and severe Hypersensitivity Reactions. These serious reactions often manifest within the first month of treatment. Due to these risks, Tiopronin is contraindicated in patients with a history of Tiopronin-induced agranulocytosis or thrombocytopenia.

Official labels also detail population-specific safety considerations. For pregnant women, use is considered only when the potential benefit outweighs the potential for documented embryo-fetal toxicity risk. Similarly, for lactating women, the unknown excretion into human milk necessitates careful assessment against the potential for adverse effects in the infant. Regulatory oversight requires ongoing laboratory monitoring of blood counts and urine protein to address the potential for hematologic toxicity and proteinuria.

Overdose and Emergency Response

Tiopronin Overdose and When to Seek Help

The information regarding acute overexposure to Tiopronin is highly limited in official government regulatory documents. The United States Food and Drug Administration (FDA) prescribing information and equivalent official sources generally do not list a specific set of clinical manifestations or symptoms that occur following a single acute overdosage event.


Official Regulatory Guidance

Category Regulatory Statement
Documented Manifestations Acute symptoms or clinical signs of overdosage are undocumented in the official regulatory sections.
Antidote Information No specific antidote is known for Tiopronin overdosage.
Emergency Management Management of overdosage consists only of symptomatic and supportive treatment.

Required Emergency Action

Any suspected Tiopronin overdosage is considered a situation that requires immediate professional evaluation. The official regulatory guidance directs that contact should be made with a poison control center or emergency room at once in the event of suspected overdosage. This mandated action reflects the necessary clinical urgency when specific acute toxicity data is absent and management relies solely on non-specific supportive care.

Therapeutic Uses of Tiopronin

What Tiopronin Treats: Main Uses and Benefits

Tiopronin is commonly used across conditions presenting with episodic or fluctuating manifestations that affect the urological system. It is applied in clinical settings that involve acute or unstable symptom patterns and may be part of supportive symptom management. Its core therapeutic use is supporting the management of the risk of cystine stone formation in patients with severe homozygous cystinuria.


Managing Conditions Characterized by Recurrent Episodes

Tiopronin is relevant in situations involving recurrent or episodic manifestations linked to a genetic metabolic imbalance. Specifically, it is applied in addressing the core challenge that leads to the formation of cystine kidney stones. This supportive therapy is considered relevant when standard symptomatic measures alone are not sufficient to help with the associated symptomatic burden. The main condition category addressed is cystinuria, where supportive management of stone formation is relevant.


Assisting with Symptoms Related to Physical Discomfort

This medication may assist with managing symptoms related to physical discomfort and noticeable physiological strain associated with recurrent stone formation. Tiopronin supports the patient during episodes of heightened symptoms and associated physiological strain. This generally contributes to improved day-to-day comfort and assists with easing the overall symptom load.

Quick Fact: Supportive care for symptoms related to Physical Discomfort and Systemic Imbalance

Regulatory References

  1. THIOLA- tiopronin tablet, sugar coated Mission Pharmacal Company - DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Tiopronin?

Patient eligibility for Tiopronin is strictly defined by regulatory guidelines and specific clinical factors. The medication is used in adults and children with severe homozygous cystinuria whose condition is not adequately managed by conservative non-pharmacological measures.


Contraindications and Restrictions

Classification Rule and Patient Group
Absolute Contraindication Patients with a known history of hypersensitivity or allergy to tiopronin (alpha-mercaptopropionylglycine) or any component of the formulation must not use this medicine.
Pediatric Restrictions Use is not approved for children under 9 years of age or those who weigh less than 20 kg.
Mandatory Discontinuation The medication must be stopped if a patient develops proteinuria (excess protein in the urine) during treatment.
Conditional Use (Caution) Geriatric patients require caution in dose selection and monitoring of renal function. Patients with pre-existing renal impairment should also use this medicine with caution.
Reproductive Status Breastfeeding is not recommended during treatment. Pregnancy status should be verified as negative before initiating therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Tiopronin interactions primarily addresses the need for administration timing separation related to specific formulations and substances, rather than formal drug-drug interactions.

Administration and Substance-Specific Constraints

Formulation Interacting Substance Official Constraint Interaction Outcome Classification
Immediate-Release Food/Meals Must be administered at least one hour before or two hours after meals. Administration-Timing Interaction
Delayed-Release Ethanol (Alcohol) Avoid consumption 2 hours before and 3 hours after taking the tablet. Exposure-Altering Interaction

The official documentation explicitly notes that the consumption of alcohol with the delayed-release formulation increases the dissolution rate of the tablet. This change in release rate is considered an exposure-altering interaction and prompts the mandatory timing restriction to mitigate risk. Conversely, the immediate-release tablet requires separation from food to manage its absorption characteristics, establishing a necessary timing rule.

Drug-Drug Interaction Status

Regulatory interaction overviews for Tiopronin indicate a lack of known clinically significant interactions with other medicinal products. No medicinal product is formally listed as contraindicated for co-administration based on drug interaction risk. Furthermore, official labeling does not specify any known CYP-mediated or transporter-based interactions for the drug.

Mechanism of Action

Tiopronin functions as an active reducing thiol agent that primarily targets the disulfide bonds of cystine. After absorption, the compound is primarily excreted into the urine, where its mechanism of action is localized.

Molecular Interaction and Cascade

The central mechanism is a thiol-disulfide exchange reaction. The free sulfhydryl group (- SH) of Tiopronin reacts with the disulfide bond ( S- S) that joins the two cysteine monomers forming the poorly soluble amino acid, cystine.

This interaction results in the formation of a mixed disulfide complex, specifically Tiopronin-cysteine (N-(2-mercaptopropionyl)glycine-cysteine disulfide).

RSH + Cys-S-S-Cys ightarrow RSS-Cys + CysSH

System-Level Physiological Consequence

The resulting Tiopronin-cysteine complex exhibits a significantly higher aqueous solubility compared to the native cystine molecule. This increase in solubility shifts the equilibrium in the urinary environment, effectively reducing the concentration of free, sparingly soluble cystine. The molecular consequence is a system-level physiological modulation that results in less precipitation of cystine crystals and a reduction in the mass of solid aggregates in the renal system.

Additionally, Tiopronin possesses intracellular antioxidant properties, acting as a scavenger of reactive oxygen species (ROS) through its thiol group, which may contribute to cellular protection.

Dosage and Administration Information

How to Use Tiopronin: Administration Guidelines

The use of Tiopronin follows specific instructions to ensure proper, monitored administration. The medicine is taken orally in a highly individualized, titration-based regimen, and it is used as part of a comprehensive treatment plan that includes other specific non-drug therapies.


Dosing and Timing Rules

Instruction Category Standard Requirement
Route and Frequency Taken orally, divided into three equal doses per day (TID).
Initial Adult Dose 800 mg total per day.
Initial Pediatric Dose 15 mg/kg per day (for those at least 9 years old or at least 20 kg), rounded to the nearest 50 mg.
Timing Relative to Meals Take at least 1 hour before or 2 hours after eating meals.
Dose Adjustment Dose must be periodically adjusted based on measuring urinary cystine concentration (e.g., to keep levels below 250 mg/L).

Administration Procedures

Capsules or tablets must be swallowed whole; they should not be crushed, chewed, cut, or dissolved, as this can affect the medicine's designed release properties. If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped to return to the regular schedule; do not take two doses at once.

Treatment requires concurrent use with a high fluid intake, alkali administration, and specific dietary modifications, as the medicine alone does not constitute the entire therapy. Furthermore, for one specific delayed-release formulation, patients are instructed to avoid alcohol consumption 2 hours before and 3 hours after taking the medicine.

Recent Clinical Evidence

Tiopronin: Recent Clinical Evidence

Tiopronin is a thiol-containing agent primarily studied for the management of severe homozygous cystinuria, a genetic disorder leading to the recurrent formation of cystine kidney stones. It is typically considered for patients who have not responded adequately to non-pharmacological measures, such as high fluid intake and dietary modification.

Mechanism of Action

Research indicates that tiopronin works by undergoing a thiol-disulfide exchange reaction with cystine in the urine. This reaction converts sparingly soluble cystine into a highly water-soluble mixed disulfide complex, thereby reducing the urinary concentration of cystine and potentially lowering the risk of stone formation.

Clinical Findings and Safety Profile

Studies have demonstrated that treatment with tiopronin is associated with a reduction in the rate of new cystine stone formation. In historical clinical experience, the rate of stone formation during tiopronin treatment was reduced compared to the pretreatment period, with efficacy guided by maintaining urinary cystine concentrations below a critical solubility limit.

Recent pharmacovigilance analysis of post-marketing data has focused on further defining the safety profile, particularly in the pediatric population. Known and documented adverse events include gastrointestinal disturbances (such as nausea and diarrhea) and dermatological reactions (rash). More serious documented risks, often requiring monitoring, include proteinuria, which is a sign of excessive protein in the urine, and hypersensitivity reactions. An enteric-coated formulation has also been developed and studied, with the aim of reducing the incidence of gastrointestinal side effects and improving patient adherence to the treatment schedule.

Key Studies & References

  1. Cystinuria: clinical practice recommendation (ERKNet)
  2. Outcomes of Tiopronin and D-Penicillamine Therapy in Pediatric Cystinuria: A Clinical Comparison of Two Cases
  3. A Summary of Current Guidelines and Future Directions for Medical Management and Monitoring of Patients with Cystinuria

Frequently Asked Questions (FAQ)

Common questions about Tiopronin (FAQ)

Q: What are the most common things people worry about when taking Tiopronin?

A: Official safety data lists common side effects documented in official sources that include nausea, diarrhea, rash, and fatigue. Regulatory guidelines also require monitoring due to the potential for serious reactions, such as changes in blood counts or proteinuria (excess protein in the urine).

Q: Are there any long-term health concerns associated with using Tiopronin for many years?

A: Official labeling addresses long-term use, and patients using the medicine for many years are subject to periodic assessments as outlined in prescribing information. These assessments check for potential long-term risks such as proteinuria and possible hematologic toxicity (changes in blood cell counts).

Q: Is it normal to feel a change in appetite after starting Tiopronin?

A: Official adverse event reports list anorexia (loss of appetite) as an effect observed in some patients during clinical trials. A change in appetite is a documented adverse event observed in some patients while using this medicine.

Q: What happens if someone suddenly stops taking Tiopronin?

A: Tiopronin is prescribed to help prevent the formation of stones in a chronic condition. Regulatory information indicates that stopping treatment, unless specifically advised, means a loss of the protective effect, which may result in the loss of the prophylactic effect against stone formation.

Q: Is Tiopronin the only option for treating cystinuria?

A: Official prescribing information references D-penicillamine when discussing dosing considerations, particularly in patients who have reacted severely to that medicine. This suggests D-penicillamine is an alternative option referenced in regulatory documents.

Q: How does the effectiveness of Tiopronin compare to general dietary changes?

A: The medicine is indicated for patients with severe cystinuria who have not responded adequately to non-pharmacological measures alone. These conservative measures include high fluid intake and dietary modification, which means the drug is typically used when those initial measures are insufficient.

Q: Does Tiopronin affect blood pressure?

A: The official adverse event reports from clinical trials do not list effects on blood pressure (high or low) among the common or uncommon reported reactions to the medicine.

Q: How quickly does Tiopronin start working after someone begins taking it?

A: Pharmacokinetic data provides information on drug absorption. For the immediate-release formulation, the concentration of the medicine in the blood is generally expected to reach its maximum concentration within approximately 1 hour after a dose.

Q: Does Tiopronin have any known effects on fertility or reproductive health?

A: Reproductive health is included as a necessary safety consideration in the official profile. Nonclinical studies, which use animal models, have been conducted to examine the potential for impairment of fertility.

Q: Are there different brand names for the medicine Tiopronin?

A: Yes, Tiopronin is the generic name for the active ingredient. According to regulatory documents, this active ingredient is available under multiple brand names, such as Thiola and Thiola EC.

Q: Is Tiopronin considered a long-term treatment or a temporary one?

A: The medicine is indicated for managing a chronic condition (severe homozygous cystinuria). Official monitoring guidelines require periodic assessments for the duration of the treatment, indicating that it is typically used for ongoing, long-term treatment.

Q: Can Tiopronin be taken by people who have liver problems?

A: Official regulatory product information states that Tiopronin should be used with caution in patients with hepatic function (liver function) impairment. Dose selection and monitoring are factors noted in this context.

Q: Are there any dietary restrictions, besides low-sodium, recommended while on Tiopronin?

A: Regulatory guidance requires this medicine to be part of a comprehensive plan that includes diet modification. Official counseling information may reference the necessity of following a low-methionine diet to maximize treatment benefit.

Q: What is the usual duration of a treatment course with Tiopronin?

A: Tiopronin is indicated to prevent stone formation in a severe, chronic metabolic disorder. Due to the nature of the condition, treatment is typically ongoing rather than a short, temporary course.

Q: Does Tiopronin cause drowsiness or tiredness?

A: The official adverse reaction list includes fatigue (tiredness) as a common side effect. However, drowsiness (somnolence) is not listed as a common or uncommon side effect in official reports.

Q: Is Tiopronin prescribed for any condition other than cystinuria?

A: Official labeling specifies the indication for the prevention of cystine stone formation in adult and pediatric patients with severe homozygous cystinuria.

Q: Does Tiopronin cause weight gain or weight loss?

A: Official safety documents list anorexia (loss of appetite) as an adverse event in some clinical trial participants. However, 'weight gain' or 'weight loss' as distinct side effects are not consistently listed among the most common adverse reactions.

Q: Can someone take Tiopronin if they are taking medicine for high cholesterol?

A: Official drug interaction overviews generally report a lack of known clinically significant interactions with other medicinal products. The only specific timing constraints detailed relate to food and alcohol with certain formulations.

Q: What are the signs that Tiopronin is working effectively?

A: The monitoring of effectiveness focuses on measuring urinary cystine concentration. The dosage is adjusted to maintain these levels below a specific concentration (e.g., 250 mg/L) to reduce the risk of stone formation.

Q: Does Tiopronin have a risk of addiction or dependence?

A: Tiopronin is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA). Consequently, the official labeling does not contain warnings regarding the risk of addiction or dependence.

Q: Why is it necessary to limit salt intake while using Tiopronin?

A: Official patient counseling information references the need for a low sodium diet as part of the total treatment plan. High salt consumption is known to increase the excretion of cystine in the urine, which may counter the drug’s effectiveness.

Q: Are there reports of Tiopronin causing changes in mood or sleep?

A: The official adverse reaction lists do not specifically include 'mood changes' or 'sleep disturbances' as common documented effects. The list does note general systemic effects such as fever and fatigue.

Q: Can people with known stomach issues (like ulcers) take Tiopronin?

A: The medicine's official safety profile includes common gastrointestinal adverse reactions, such as nausea and diarrhea. These documented gastrointestinal effects are a consideration noted in the official product information.

Q: Is Tiopronin available over the counter anywhere?

A: Regulatory status confirms that Tiopronin is classified as a prescription-only medication in the United States. It is not available for purchase over the counter.

Q: Are there any known issues with Tiopronin and dental health?

A: The official adverse reaction list includes oral ulcers (mouth sores) as a side effect documented in clinical trials, which relates to oral health.

Q: How long does Tiopronin stay in the body after the last dose?

A: Pharmacokinetic studies estimate that approximately 78% of the administered dose is eliminated through the urine within 72 hours following a single dose.

Q: Can people with diabetes safely use Tiopronin?

A: Official labeling contains no specific warnings or contraindications related to diabetes. Precautions are mentioned for conditions like renal or hepatic impairment, but not specifically for diabetes status.

Q: Why is hydration so important when taking Tiopronin?

A: Tiopronin is required to be used in combination with high fluid intake as part of the therapy. The medicine works by converting insoluble cystine into a highly water-soluble complex, and high fluid intake is required to facilitate its efficient excretion in the urine.

How should Tiopronin be stored and disposed of?

Storage and Disposal Instructions

Tiopronin tablets must be kept at controlled room temperature, which is 25 C (77 F), with permitted fluctuations between 15 C and 30 C (59 F and 86 F). The product requires protection from freezing, excessive heat, moisture, and direct light.

Handling and Stability

The medication must be stored in a closed container and kept out of the reach of children. All Tiopronin must be discarded after the expiration date.

For the delayed-release formulation, if a tablet is crushed and mixed with applesauce, the mixture should be administered immediately. If immediate use is not possible, the mixture has a maximum 2-hour stability limit when stored in a refrigerator, after which it must be discarded.

Official Disposal Rules

Unused or expired Tiopronin should be disposed of according to local regulations. Patients are advised to consult a healthcare professional for specific guidance on discarding unneeded medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tiopronin found in:

A-Z Index: